



Corporate Briefing Session

OCTOBER 21, 2022

LAHORE



CONTENTS



Company Profile



Pharmaceutical Industry Highlights



Collaborations and Product Portfolio



Financial Performance



Our Disease Awareness Initiatives



Questions and Answers Session



Our Community Care Initiatives





COMPANY PROFILE



COMPANY INFORMATION

Incorporation



Incorporated in 1954 as Private Limited Company

Enlistment



First Pakistani Pharmaceutical Co. Listed on Stock Exchange in 1960 Principle Business



Primarily Engaged in the Manufacture, Imports and Sale of Pharmaceutical Products and Medical Devices

Latest Therapies



Have Consistent Track Record of Bringing Latest Therapies in Pakistan at Affordable Prices



OUR VISION, MISSION AND VALUES

Our Vision


We will strive to attain market leadership by putting patients first and seeing every day as a new opportunity to earn trust and credibility.

Our Mission & Values Statement

We aim to improve the quality of life by providing innovative healthcare solutions, ensuring patient access to treatment and cure. In doing so, we will:

- Enhance shareholder value
- Lead in employee development
- Collaborate for excellence
- Be ethical & transparent







MANUFACTURING CAPABILITIES

cGMP Compliant Manufacturing Facilities:

We have two cGMP compliant manufacturing facilities in Pakistan, to cater the production of tablets, capsules, syrups, suspensions, ointments and injectables.

Maintaining Highest Quality Standards:

In order to maintain quality standards with world's most reputed pharma companies, Ferozsons only sources raw materials from cGMP compliant manufacturers.

BMR of Production Facilities:

Over the last few years, investment amounting to Rs. 2.5 billion has been made as part of BMR of existing manufacturing facilities. Alongside, a major expansion in our subsidiary BFBL is underway currently.











MANUFACTURING CAPABILITIES

State-of-the-Art Pharmaceutical Oral Dosage Manufacturing Unit Nowshera, KPK Province









MANUFACTURING CAPABILITIES

State-of-the-Art Pharmaceutical Injectables Manufacturing Unit Lahore, Punjab





MANUFACTURING CAPABILITIES – BF EXPANSION SNAPSHOT













PEOPLE TRUST US

PRESENCE IN INTERNATIONAL MARKETS








COLLABORATIONS & PRODUCT PORTFOLIO



COLLABORATIONS





PRODUCT PORTFOLIO – PHARMA & OTC



PEOPLE TRUST US

PRODUCT PORTFOLIO – INJECTABLES





PRODUCT PORTFOLIO – MEDICAL DEVICES

Medical devices of following segments are marketed:



New Brands In Our Portfolio










DISEASE AWARENESS INITIATIVES

Karachi Monuments Illuminated To Celebrate World Heart Day








PEOPLE TRUST US

DISEASE AWARENESS INITIATIVES

Partnered With Leading Diabetes Institutions To Launch 'Stop Diabetes' Campaign Across Pakistan









DISEASE AWARENESS INITIATIVES

Pinktober – Ferozsons Rallies For Breast Cancer Awareness











OUR COMMUNITY CARE INITIATIVES



PARTNERSHIP WITH RIZQ

Ferozsons Laboratories Limited has collaborated with Rizq, under its Omega initiative to combat hunger. We have taken this step to provide nutrition to the underprivileged families and help to reduce number of malnourished people in Pakistan.





MOU FOR EARLY DIAGNOSTICS OF DIABETES

An MoU was signed between Ferozsons and the Baqai Institute of Diabetology and Endocrinology (BIDE) to launch 'fast-track pathway' for early diagnostics of diabetic foot patients across Pakistan.









PHARMACEUTICAL INDUSTRY HIGHLIGHTS



PHARMACEUTICAL INDUSTRY HIGHLIGHTS


1	Market Size	Overall Pakistan's Retail Pharma Market stands at Rs. 655.94 Billion.
	Growth and	Crowth over last veer stands at 17 160/ (approx), whereas last 5 veers
2	CAGR	Growth over last year stands at 17.16% (approx.), whereas last 5 years CAGR stands at 15.16%.
3	Top Corporates	Approx. 94% market share is held by top 72 pharma corporates in Pakistan.
4	Market Share Top Channels	Retail pharmacy channel captures share of approx. 60%.
5	New Launches	289 new products have been launched, which nearly contributes 0.61% of the market share.






FEOPLE TRUST US


FINANCIAL PERFORMANCE – YEAR ENDED 30 JUN 2022 (STANDALONE)






PEOPLE TRUST US


FINANCIAL PERFORMANCE - YEAR ENDED 30 JUN 2022 (GROUP)





PEOPLE TRUST US

PAYOUT TO INVESTORS – LAST SIX YEARS







QUESTIONS AND ANSWERS SESSION



THANK YOU

